493 related articles for article (PubMed ID: 11663254)
41. Proposal on waiver of informed consent poses major issues for research ethics.
Maloney DM
Hum Res Rep; 1997 Sep; 12(9):1-3. PubMed ID: 11660533
[No Abstract] [Full Text] [Related]
42. Can children be enrolled in a placebo-controlled randomized clinical trial of synthetic growth hormone?
Prentice ED; Antonson DL; Jameton A; Graber B; Sears T
IRB; 1989; 11(1):6-10. PubMed ID: 11659085
[No Abstract] [Full Text] [Related]
43. Continuing review of research involving human subjects: approach to the problem and remaining areas of concern.
Gordon B; Prentice E
IRB; 1997; 19(2):8-11. PubMed ID: 11655323
[No Abstract] [Full Text] [Related]
44. IRB jurisdiction and limits on IRB actions.
Hershey N; Cann CI; Rothman KJ
IRB; 1985; 7(2):7-9. PubMed ID: 11649624
[No Abstract] [Full Text] [Related]
45. Institutional review board approval required by rule.
Maloney DM
Hum Res Rep; 1996 Aug; 11(8):3. PubMed ID: 11654440
[No Abstract] [Full Text] [Related]
46. Obtaining "informed consent": controversy over radiation tests focuses attention on rules for human subjects.
Wheeler DL
Chron High Educ; 1994 Jan; 40():8-9, 16. PubMed ID: 11658067
[No Abstract] [Full Text] [Related]
47. FDA revises informed consent regulations for emergency research.
Menasché A; Levine RJ
IRB; 1995; 17(5-6):19-22. PubMed ID: 11653359
[No Abstract] [Full Text] [Related]
48. Human experimentation regulations: too little or too much?
FAS Prof Bull; 1975 Feb; 3(2):1-8. PubMed ID: 11664436
[No Abstract] [Full Text] [Related]
49. Worlds apart.
Chalmers TC; MacDonald MG
Trial; 1975; 11(6):27-28+. PubMed ID: 11662205
[No Abstract] [Full Text] [Related]
50. Protection of persons undergoing biomedical research: Code of Public Health; Book IIA.
France
Bull Med Ethics; 1991 Mar; No. 66():8-11. PubMed ID: 11651087
[No Abstract] [Full Text] [Related]
51. Federal investigation concludes that institutional review boards are in trouble.
Maloney DM
Hum Res Rep; 1998 Aug; 13(8):1-2. PubMed ID: 11657190
[No Abstract] [Full Text] [Related]
52. Federal policy for the protection of human subjects. Final rule.
Fed Regist; 1991 Jun; 56(117):28003-18. PubMed ID: 10112214
[TBL] [Abstract][Full Text] [Related]
53. Research compliance changes will affect rules on protection of human subjects.
Maloney DM
Hum Res Rep; 1999 May; 14(5):1-2. PubMed ID: 11657776
[No Abstract] [Full Text] [Related]
54. Medical science, the clinical trial and society.
Marston RQ
Hastings Cent Rep; 1973 Apr; 3(2):1-4. PubMed ID: 11660997
[No Abstract] [Full Text] [Related]
55. Federal report says protection of human subjects is threatened by numerous factors.
Maloney DM
Hum Res Rep; 1996 May; 11(5):1-3. PubMed ID: 11654438
[No Abstract] [Full Text] [Related]
56. Half-full or half-empty? Evaluating IRB performance.
Mishkin B; Ariand N
Prof Ethics Rep; 1998; 11(3):4-7. PubMed ID: 11657925
[No Abstract] [Full Text] [Related]
57. Advice on compensation: one IRB's response to DHEW's 'interim final regulation'.
Levine RJ
IRB; 1979 Mar; 1(1):5. PubMed ID: 11662737
[No Abstract] [Full Text] [Related]
58. Psychosurgery: the law's response.
Annas GJ; Glantz LH
Boston Univ Law Rev; 1974 Mar; 54(2):249-67. PubMed ID: 11661084
[No Abstract] [Full Text] [Related]
59. The IRB's role in assessing the generalizability of non-NIH-funded clinical trials.
Weijer C
IRB; 1998; 20(2-3):1-5. PubMed ID: 11656912
[No Abstract] [Full Text] [Related]
60. The NIH trials of growth hormone for short stature.
Tauer CA
IRB; 1994 May; 16(3):1-9. PubMed ID: 11659923
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
